
Opinion|Videos|February 25, 2025
Future Perspectives on TCR Therapies for Sarcomas and Other Solid Tumors
A panelist discusses how T-cell receptor (TCR) therapies are likely to evolve through innovations such as allogeneic approaches, enhanced manufacturing processes, identification of new target antigens, and potential combinations with other immunotherapies, which could expand their applicability across multiple sarcoma subtypes and other solid tumors while improving accessibility and efficacy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do you see the future of TCR therapies evolving for sarcomas and other solid tumors?
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5

